1. The delayed neurotoxic effects of some organophosphorus compounds are associated with phosphorylation of the active site of a nervous-tissue enzyme capable of hydrolysing phenyl phenylacetate. 2. Neurotoxic organophosphorus compounds and some carbamates and sulphonyl fluorides progressively inhibit the enzyme, attaching a substituent covalently at the active site. 3. Prolonged inhibition of the enzyme by phenyl N-benzyl-N-methylcarbamate or phenylmethanesulphonyl fluoride does not lead to neurotoxic effects. 4 . Prior inhibition of the enzyme by carbamates or sulphonyl fluorides in vivo prevents the neurotoxic effects of several organophosphorus compounds. 5. After dosage of hens with protective compounds, protection lasts until about 70% of the enzyme site again becomes available for phosphorylation. 6. Reaction of all the inhibitors at the active site of the enzyme leads to the same inhibitory effect with respect to hydrolysis of phenyl phenylacetate but does not in all cases lead to delayed neurotoxicity. It is concluded that the nature of the group substituted at the enzyme active site determines the toxic response.
Numerous organophosphorus esters cause delayed neurotoxic effects in hens 10-14 days after administration (see review by Davies, 1963; Aldridge & Barnes, 1967) . The effects are seen clinically as ataxia and histologically as a dyingback of some long axons of the nervous system. Effective compounds are all inhibitors of esterases or are converted into inhibitors in vivo (Aldridge, 1954) , but not all inhibitors of esterases are neurotoxic. Of the inhibitors mentioned frequently in this paper DFP* and Mipafox cause ataxia whereas tetraethyl pyrophosphate and paraoxon do not.
Neurotoxic effects have been correlated with phosphorylation of a brain protein shortly after dosing: this protein can be selectively phosphorylated and assayed in vitro by using [32P]DFP (Johnson, 1967 (Johnson, , 1969a . The protein catalyses hydrolysis of phenyl phenylacetate in vitro, and a large variety of neurotoxic organophosphorus compounds inhibit this enzyme in vivo whereas non-neurotoxic analogues do not (Johnson, 1968 (Johnson, , 1969b . Certain carbamates inhibit the esterase in vitro. After dosage of hens with such carbamates, esterase activity in vivo was decreased but returned to normal within 1-36h, depending on the structure of the carbamate used, and no neurotoxic effects were seen. These rates of return contrast with a much lower rate after inhibition by DFP in vivo. Delayed neurotoxic effects of DFP were prevented by predosing hens with phenyl benzylcarbamate shortly before DFP (Johnson & Lauwerys, 1969) , and the protective effect persisted until the esterase activity had returned to about 70 % of normal at the time when DFP was given. It was concluded that neurotoxic organophosphorus compounds, phenyl phenylacetate and phenyl benzylcarbamate all reacted at the active site of the 'neurotoxic esterase' and it was deduced that prolonged inhibition of this esterase caused the metabolic disturbance leading to dying-back of axons (Johnson, 1969c) . This paper reports further experiments confirming the identity of the 'neurotoxic phosphorylation site' and the 'neurotoxic esterase'. By studies with some inhibitors that do not contain phosphorus but do cause prolonged inhibition of the esterase it has been shown that the neurotoxic effect is a result of phosphorylation as such and not a consequence of prolonged deficiency of the esterase activity.
MATERIALS AND METHODS
Chemical8. Tri-n-butyl The washed phenyl N-benzyl-N-methylcarbamate contained an impurity showing an -NH-band absorption in the i.r. spectrum, so it was dissolved in diethyl ether and passed through a column (27cm x 4cm) of activated alumina (200-400 mesh; heated overnight at 135°C before use): the impurity was firmly bound while the pure product passed unretarded and was obtained free of ether by evaporating the effluent in a stream of warm N2; it was not distilled. I.r. spectra of the monosubstituted carbamates had prominent bands characteristic both of carbonyl and -NH-groups, whereas the disubstituted carbamate gave the carbonyl band but not the -NHband. n-Butanesulphonyl bromide was prepared from butan-l-ol, thiourea and conc. HBr by the general method (B) of Johnson & Sprague (1936) : the paleyellow product distilled over the range 72-98°C/2mmHg (yield 24% based on thiourea); it had strong i.r. absorption at 1160 and 1350 cm-' characteristic ofthe sulphonyl group (Bellamy, 1958) and liberated bromine on warming with conc. HNO3. The crude n-butanesulphonyl bromide (32mmol) was converted into the fluoride by stirring with finely powdered anhydrous NaF (160mmol) in dimethylformamide for 6h at 1000C (general method of Fahrney & Gold, 1963) . The colourless purified product (yield 25%) distilled at 62-66°C/12mmHg, had sulphonyl bands in the i.r. spectrum similar to those of the bromide, but did not yield bromine on treatment with conc. HNO3.
Benzenesulphonyl fluoride (b.p. 70°C/3 mmHg) was prepared similarly from benzenesulphonyl chloride.
Henm, dosing and neurotoxicity testing. Adult hens weighing 2.0-2.6 kg were used and all details were as described previously (Johnson, 1969a,b) . Protective pretreatment against acute cholinergic effects of DFP and Mipafox was with eserine and atropine as described previously (Johnson, 1969b) were as described previously (Johnson, 1969b) 
RESULTS
Further evidence that a pho8phorylation site and an e8tera8e are involved in delayed neurotoxicity. Previous studies showed that both the 'neurotoxic phosphorylation site' and the activity of 'neurotoxic esterase' were substantially eliminated in vivo by doses of a number of neurotoxic organophosphorus compounds, but were only slightly affected by doses of non-neurotoxic analogues (Johnson, 1969a, b) . The effects of three more compounds on either the site or the esterase are shown in Table 1 and support the previous conclusion. Thus after a nonneurotoxic dose of DEF the esterase activity was decreased only to 65% of normal but after a 524 1970 Table 3 shows that whereas in vivo the activity of the esterase returns to normal quite rapidly after dosage with carbamates, the rate of return after a dose of phenylmethanesulphonyl fluoride cannot be distinguished from that after DFP.
Carbamate and sulphonyl fluoride inhibitors and delayed neurotoxicity. It has previously been shown that challenge doses of DFP given to hens during the comparatively brief period that the 'neurotoxic esterase' was inhibited by phenyl benzylcarbamate failed to cause ataxia (Johnson & Lauwerys, 1969) . It was also shown that the carbamate did not prevent access of [32P]DFP to the brain. Table 4 shows that sensitivity to DFP returned when about 70% of total esterase activity became available for inhibition by DFP. The Table also shows that an intravenous dose of phenyl n-butylcarbamate (510B,mol/kg) protected against DFP given 24h later, when esterase activity was 39% ofcontrol, and gave partial protection after 48h, at which time the esterase activity was 78% of control. Phenyl N-benzyl-N-methylcarbamate also protected against DFP (Table 4) Table 3. was still substantial 17 h after a single dose (Table 3) . This compound was therefore administered in divided doses to hens, so that a total of 5 mmol/kg was given in 14 oral doses during 17 days. Esterase activity was 25% and 32% ofnormal when measured 17h after the first and last doses respectively. No ataxia developed in a single test hen during 18 days from the first dose. Esterase activity probably fluctuated considerably during the periods between doses, and it was thought possible that to cause ataxia there must be a severe continuous deficiency of activity for a few days, as occurs after a single dose of DFP. (Table 3 ) and no ataxia occurred in any of three birds that were observed for 3 weeks after receiving such a dose. The return of enzyme activity to normal was not followed in detail, but it was akin to the rate after phenylmethanesulphonyl fluoride.
It is evident that prolonged inhibition of the brain 'neurotoxic esterase' does not inevitably cause a metabolic disturbance leading to dying-back of long axons, and this is contrary to previous conclusions (Johnson, 1969b,c) .
The histological lesions associated with delayed neurotoxicity are seen in spinal cord and peripheral nerve, rather than in brain. The biochemical correlations established so far have been based on studies with homogenates of whole brain. A measurable but low activity of 'neurotoxic esterase' has been found in sciatic-nerve homogenate (M. K. Johnson, unpublished work), but routine assay is not practicable. It has been shown that activity in spinal cord of both phosphorylation site and esterase is inhibited in vivo by both DFP (Johnson, 1969b) and 2-methylphenyl diphenyl phosphate (M. K. Johnson, unpublished work). At 3 days after inhibitory doses of DFP or phenylmethanesulphonyl fluoride activity of the esterase in spinal cord was respectively 33% and 41% of control, compared with 30-40% in brain. There is no reason therefore to believe that the present anomaly arises from studying brain instead of spinal cord or sciatic nerve.
One possible interpretation of the failure of phenylmethanesulphonyl fluoride to cause ataxia is that inhibition of the esterase is not connected with the lesion in spite of the correlations that have been accumulated. That this is not so is shown by the fact that, when birds dosed first with phenylmethanesulphonyl fluoride are given a challenge dose of DFP, no ataxia occurs (Table 4 ). The effect is exactly analogous to protection by carbamates, but the duration is greatly extended. Thus after a single subcutaneous dose of phenylmethanesulphonyl fluoride (173,umol/kg) no ataxia was seen when DFP (9.5 ,umol/kg) was given subcutaneously at any time up to 5 days after; partial protection was observed when DFP was given after 7 days, at which time 67% of normal esterase activity was available for inhibition by DFP (Table  4) . Moreover, the same dose protected all of three birds against the neurotoxic effects of Mipafox (137,umol/kg) given subcutaneously 1 day after, and protected two out of three against 2-methylphenyl diphenyl phosphate (350/,mol/kg) given orally and gave partial protection to the remaining bird. No protection occurred in any of three hens ifthe same dose ofphenylmethanesulphonyl fluoride was given 1 h after DFP. It is reasonable to conclude that inhibition by phenylmethanesulphonyl fluoride prevents subsequent phosphorylation ofthe esterase by several different neurotoxic organophosphorus esters. The return of DFP-sensitivity of the birds can again be correlated with availability of about 70% of esterase activity (Table 4) and presumably with availability of 70% of the phosphorylation site. Table 4 shows that n-butanesulphonyl fluoride also protected against DFP. Further evidence that phenylmethanesulphonyl fluoride, phenyl benzylcarbamate and DFP all act at the same site is obtained from the results in Table 5 : thus when phenylmethanesulphonyl fluoride (21 ,umol/kg) was given intravenously to hens inhibition was typically prolonged and birds given a challenge dose of DFP 28h afterwards did not become ataxic. However, Table 5 also shows that if phenyl benzylcarbamate (264,mol/kg) is injected intravenously lh before the phenylmethanesulphonyl fluoride then the Table 5 . Prevention of protective effect of phenytmeethane8utphonyt benzylcarbamate fluoride by prior admini8tration of phenyl Groups of four hens were dosed intravenously as indicated with test compounds dissolved in glycerol formal. 'Neurotoxic esterase' activity in homogenate of a single brain was determined 1.5 h and 28 h after the second dose and calculated as percentage activity of homogenate from an undosed bird assayed at the same time. At 28h after dosage, two hens of each group received DFP (9.5,umol/kg) subcutaneously after prophylactic treatment with eserine and atropine as described in the Materials and Methods section. Clinical assessment of ataxia was made after 2-3 weeks.
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Phenylmethanesulphonyl fluoride (21 ,umol/kg) intravenously 1 h after solvent INHIBITORS AND DELAYED NEUROTOXICITY degree and duration of inhibition are identical with those after the carbamate alone, and similarly dosed birds became ataxic when given a challenge dose of DFP at 28h. This experiment has been repeated three times with slight variations of dose, giving qualitatively similar results. Also it was shown that 24h after a neurotoxic subcutaneous dose of DFP (9.5,umol/kg) the esterase activity was 11% of normal and less than 10% of the 'neurotoxic phosphorylation site' was available, but when the DFP was given 1 h after an intravenous dose of phenyl benzylcarbamate (220,umol/kg) the respective values were 63 and 80% of normal.
DISCUSSION
The procedures used in the present work are complex and the conclusions to be drawn are surprising. I have therefore listed below a summary of the facts that are clearly established.
(1) Delayed neurotoxicity is associated both with phosphorylation of a protein site that can be identified by a specific assay and with inhibition of an esterase that can be specifically assayed. The esterase behaves as a homogeneous enzyme towards Mipafox in vitro (Johnson, 1969b) . Complete correlation of delayed neurotoxicity with phosphorylation of the site has been established in vivo by using 16 organophosphorus compounds having a large variety of chemical structure (Johnson, 1969a,b ; this paper, Table 1 ). Correlation of delayed neurotoxicity with inhibition of the esterase is also supported by studies with 16 organophosphorus compounds in vivo (Johnson, 1969b, and this paper) .
(2) Phosphorylation of the 'neurotoxic site' and hydrolysis of phenyl phenylacetate by the 'neurotoxic esterase' are two properties of a single site associated with delayed neurotoxicity. There are four lines of evidence. (a) Both parameters were affected to a similar extent in vivo and in vitro by numerous compounds. Fig. 1 shows the close correlation of effect of organophosphorus compounds (fourteen in vivo), carbamates (three in vitro and in vivo) and sulphonyl fluorides (three in vitro and in vivo) on the site and esterase. The data are drawn from Tables 1 and 2 and from previously published work (Johnson, 1969a,b Tables 1 and 2 and text of this paper and from Johnson (1969a,b, (Aldridge, 1969 (Sanger, 1963; Gold, 1965; Cardinaud & Baker, 1970) . (d) At 24h after a neurotoxic dose of DFP both parameters were profoundly affected and ataxia developed 8-14 days afterwards. When the DFP was preceded by a dose of phenyl benzylcarbamate both parameters were only slightly affected at 24h and no ataxia developed (see the Results section).
(3) Carbamate and sulphonyl fluoride inhibitors of the 'neurotoxic esterase' react at the same site as inhibitory organophosphorus compounds. This is shown by the following. (a) The evidence of 2(c) and 2(d) above. (b) The inhibitory carbamates and sulphonyl fluorides produce inhibition in vivo lasting from a few hours to several days, and this can be correlated with the duration oftheir capacity to prevent neurotoxic effects of DFP. Protection lasts until about 70% of the site is available to DFP (Table 4 and the Results section). This correlates with the fact that neurotoxic effects of organophosphorus compounds are not seen unless inhibition of the enzyme site shortly after the dose is at least 70% (Johnson, 1969a,b;  and this paper, Table 1 ). (c) Phenylmethanesulphonyl fluoride protects against neurotoxic effects when given before DFP, but not when given after.
(4) After the enzyme site has been phosphorylated or phosphonylated in vivo ataxia follows. This has been established positively with 11 neurotoxic compounds and negatively with ten other compounds that are not neurotoxic although they are of related chemical structure to the neurotoxic ones and are all active esterase inhibitors in vivo (Johnson 1969a,b ; and this paper, Table 1 ). Also, prior carbamoylation or sulphonation of the enzyme site in vivo prevents both the phosphorylative inhibition and the neurotoxic effects of a subsequent dose of several neurotoxic compounds (see the Results section and Table 4 ).
(5) After the enzyme site has been carbamoylated or sulphonated in vivo ataxia does not follow. This is difficult to establish incontrovertibly for carbamates, where repeated doses had to be given to achieve inhibition as long-lasting as that caused by a single dose of DFP, and it is probable that inhibition was not greater than 75% for any long continuous period. This objection does not apply to phenylmethanesulphonyl fluoride and probably not to n-butanesulphonyl fluoride. It is clear that phenylmethanesulphonyl fluoride is not even subclinically effective, for when the enzyme was only 40-50% inhibited by this compound it was not possible to produce ataxia by 'topping-up' the inhibition to near 100% with a dose of DFP, nor did extension of the period of profound inhibition (>80%) of the enzyme to more than two weeks by repeated doses of phenylmethanesulphonyl fluoride produce any neurotoxic effect.
Toxic effects that follow inhibition of an enzyme in vivo may be due to accumulation of an intermediate of metabolism rather than to lack of end product (e.g. convulsive effects due to accumulation of acetylcholine after poisoning by anticholinesterases). If delayed neurotoxicity caused by organophosphorus compounds were due to an accumulated intermediate, then it could be postulated that phenylmethanesulphonyl fluoride is not neurotoxic because it might inhibit formation of the toxic intermediate as well as inhibiting the esterase. However, this explanation is eliminated, since administration of phenylmethanesulphonyl fluoride shortly after DFP did not prevent neurotoxic effects.
(6) The inhibitory effects of DFP and phenylmethanesulphonyl fluoride in vivo are similar in brain and spinal cord.
(7) There is no essential difference between the protein bearing a phosphonyl, phosphoryl, carbamoyl or sulphonyl group at its active site, with respect to hydrolysis of phenyl phenylacetate in vitro or in vivo.
(8) There is an essential metabolic difference in vivo between the protein bearing a phosphonyl or phosphoryl group at its active site and the same protein bearing a carbamoyl or sulphonyl group at the same active site. There is no information on the nature of this difference that is directly associated with delayed neurotoxicity. All known neurotoxic esters are derived from phosphoric acid or phosphonic acid. It may be possible to synthesize phenyl phenylacetate esterase inhibitors derived from other acids and to explore further the relationship of neurotoxic effects to the nature of the substituent that is covalently bound to the active site.
It should be noted that, although prolonged inhibition of the esterase is not a sufficient indicator of a potentially neurotoxic ester, failure to inhibit the 'neurotoxic esterase' in vivo may still be taken as an indication that an organophosphorus compound is not neurotoxic at that dosage. The biochemical test has the advantage that the extent of inhibition can be determined and interpreted, whereas the clinical test is 'all-or-none'.
